Author(s)	Sample size (experimental/ control)	Patient enrollment time	Experimental	Control	Duration	Outcome measures
Chen et al., 2020	35/35	2020.2.28-2020.3.31	LHQW capsule (1.4 g Bid)	Arbidol	15 days	СТ
Cheng et al., 2020	51/51	2020.1.1-2020.1.31	LHQW granule (6 g Tid) + C	Chemical drugs	7 days	CT, fever, cough, fatigue, expectoration, shortness of breath, dyspnea, chest distress, inappetence, nausea, muscular soreness, exacerbation rate
Fang et al., 2020	42/41	2020.1.28-2020.3.31	LHQW granule (6 g Tid) + C	Chemical drugs	5-7 days	Fever, fatigue, expectoration, shortness of breath, rhinobyon, rhinorrhea, muscular soreness
Hu et al., 2020	142/142	2020.2.2-2020.2.15	LHQW capsule (1.4 g Tid) + C	Chemical drugs	14 days	СТ
Lv et al., 2020	63/38	2020.1.1-2020.2.28	LHQW granule (6 g Tid) + C	Chemical drugs	10 days	Expectoration, shortness of breath dyspnea, chest distress, rhinobyon, rhinorrhea, sore throat, inappetence, nausea, emesis, diarrhea, muscular soreness, headache, exacerbation rate
Xu et al., 2020	26/26	2020.1.29-2020.2.28	LHQW capsule (1.4 g Tid) + C	Chemical drugs	7 days	СТ
Yao et al., 2020	21/21	2020.1.11-2020.1.30	LHQW granule (6 g Tid) + C	Chemical drugs	NR	Fever, cough, fatigue, expectoration, shortness of breath, dyspnea, chest distress, rhinobyon, rhinorrhea, sore throat, inappetence, nausea, emesis, diarrhea, muscular soreness, headache


Appendix 2.	Characteristic of the 9	Trials Included in	the Meta-Analysis
-------------	-------------------------	---------------------------	-------------------

Yu and Li et al.,	147/148	2020.2.17-2020.3.6	LHQW granule (6 g Tid) + C	Chemical	7 days	CT, exacerbation rate
2020				drugs		
Yu and Ren et al.,	85/38	2020.2.17-2020.3.6	LHQW capsule (1.4 g Tid)	Arbidol	Indeterminacy	Exacerbation rate
2020						


Notes: C: control group; NR: not reported.

	References (scores)							
Items	Cheng et al.,	Fang et al.,	Lv et al., 2020	Xu et al., 2020	Yao et al.,	Yu and Ren		
	2020	2020			2020	et al., 2020		
Selection of participants (4 scores)								
Representativeness of the exposure group	1	1	1	1	1	1		
Selection of non-exposed groups	1	1	1	1	1	1		
Determination of exposure factors	1	1	1	1	1	1		
There were no outcome indicators to look for at the start of the study	0	0	0	0	0	0		
Intergroup comparability (2 scores)								
Comparability between exposed and non-exposed groups was	2	2	2	2	2	2		
considered in the design and statistical analysis								
Outcome measurement (3 scores)								
Evaluation of outcomes	1	1	1	1	1	1		
Follow-up was long enough	0	0	0	0	0	0		
Complete follow-up of the exposure group and the exposure group	0	0	0	0	0	0		
Total	6	6	6	6	6	6		

Appendix 3. Results of Quality Assessment for Retrospective Studies by Using NOS Scale



Appendix 4. Inverted Funnel Plot of LHQW in Treatment of COVID-19 for Disappearance Rate of Primary Symptoms



Appendix 5. Forest Plot of the Trials Showing Adverse Reaction in LCWC vs. CD